Oncoinvent

Mindre end 1K følgere

ONCIN

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Oncoinvent is a clinical phase radiopharmaceutical company developing treatments for solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides to deliver radiation directly to cancer cells. The Company's product candidate, Radspherin®, is an alpha radiation therapy candidate designed for the local treatment of cancer that has spread to body cavities. Oncoinvent has its headquarters in Oslo.

Markedsværdi

-

Aktieomsætning

-

Omsætning

850 t

EBIT %

-17.791,76 %

P/E

-

Udbytteafkast, %

-

Finanskalender

26.2

2026

Årsrapport '25

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelse29.10.2025, 16.38

Oncoinvent AS: Merger of BerGenBio and Oncoinvent completed

Selskabsmeddelelse29.10.2025, 14.16

Oncoinvent AS: Oncoinvent Presents Final Safety and Efficacy Results from the Phase 1/2a Trial of Radspherin® to Treat Colorectal Cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies

Selskabsmeddelelse29.10.2025, 06.00

Oncoinvent AS: BerGenBio and Oncoinvent - Last day of trading in the shares of Oncoinvent

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse24.10.2025, 05.59

Oncoinvent AS: BerGenBio and Oncoinvent - Key Dates for Completion of Merger

Selskabsmeddelelse20.10.2025, 08.00

ONCIN: Financial calendar

Selskabsmeddelelse8.10.2025, 05.00

Oncoinvent AS: Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Treat Ovarian Cancer

Selskabsmeddelelse29.8.2025, 05.00

Oncoinvent AS: Thor Medical and Oncoinvent Enter Strategic Thorium-228 Supply Agreement

Selskabsmeddelelse27.8.2025, 05.00

Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer

Selskabsmeddelelse22.8.2025, 10.22

Oncoinvent ASA invites to a webcast presentation of 1H 2025 on Wednesday 27 August 2025

Selskabsmeddelelse4.8.2025, 11.53

Oncoinvent AS: Oncoinvent shareholders approve the merger plan with BerGenBio

Selskabsmeddelelse3.7.2025, 13.45

Oncoinvent ASA: Notice of Extraordinary General Meeting

Selskabsmeddelelse30.6.2025, 20.11

Oncoinvent AS: Announcement of fully underwritten rights issue

Selskabsmeddelelse30.6.2025, 20.01

Oncoinvent AS: BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue

Selskabsmeddelelse18.6.2025, 06.01

Oncoinvent (ONCIN): Invitation to Presentation of Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases

Selskabsmeddelelse18.6.2025, 05.00

ONCIN: Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases

Selskabsmeddelelse14.5.2025, 12.39

ONCIN: Minutes from the annual general meeting 2025

Selskabsmeddelelse30.4.2025, 11.41

ONCIN: Notice of Annual General Meeting

Selskabsmeddelelse28.4.2025, 18.22

Oncoinvent ASA: Annual Report 2024

Selskabsmeddelelse28.4.2025, 06.05

Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update

Selskabsmeddelelse28.4.2025, 06.00

Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.